Xofluza 20mg & 40mg Film-coated tablets
PDF Leaflet Revision Date: 05 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment and post-exposure prophylaxis of influenza in patients aged 12 and above.
Dosage (summary)
Single dose: 40 mg for 40-<80 kg; 80 mg for u226580 kg. No adjustments for elderly or renal impairment.
Onset of Action / Duration
Onset: within 48 hours of symptom onset.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Avoid in pregnancy; safety during lactation not established.
Key Drug Interactions
- Avoid with polyvalent cation products
- Itraconazole may increase levels
Contraindications
- Hypersensitivity to baloxavir marboxil or excipients
Common side effects
- Diarrhoea
- Bronchitis
- Nausea
- Nasopharyngitis
- Headache
Counselling Points
- Take within 48 hours of symptom onset
- Avoid dairy and certain supplements
- Report any allergic reactions
Serious warnings
- Potential for hypersensitivity reactions
Important Disclaimer
The Xofluza 20mg & 40mg Film-coated tablets professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
